Canada approves cardiac surgery adhesion barrier
This article was originally published in The Gray Sheet
Executive Summary
SyntheMed's Repel-CV bioabsorbable adhesion barrier film, for preventing formation of internal scar tissue after cardiac surgery, gains Canadian approval for pediatric patients July 15. Montreal-based distributor Force3 Medicale will market the device in Canada, where an estimated 2,000 pediatric patients have heart surgery annually, according to SyntheMed CEO Bob Hickey. The firm expects U.S. PMA approval for the pediatric indication by the end of the third quarter following receipt on an "approvable" letter from FDA last November (1"The Gray Sheet" Sept. 24, 2007, p. 6). SyntheMed is simultaneously working to gain FDA approval for an adult indication, which offers a significantly larger market, though Hickey could not offer a timeline
You may also be interested in...
FDA Panel: Cardiac Surgery Adhesion Barrier Use Should Be Limited To Kids
SyntheMed's Repel-CV cardiac surgery adhesion barrier should be approved only for pediatric patients since pivotal trial data on newborns cannot be extrapolated to the adult population, FDA's Circulatory System Devices advisory panel recommended Sept. 19
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.